STOCK TITAN

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, has announced its participation in the Stifel Virtual Inflammation & Immunology Summit on September 17 & 18. The company will present on Tuesday, September 17, at 1:00 pm PT / 4:00 pm ET, providing an overview of its:

  • Multi-cytokine inhibitor programs and platform
  • Focus on dermatological and gastrointestinal indications
  • Ongoing development of itolizumab in partnership with Ono Pharmaceutical
  • Ono's pending option exercise decision to potentially acquire Equillium's rights to itolizumab

Management will be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible on the company's website, with an archived replay available for 90 days.

Equillium, Inc. (Nasdaq: EQ), una società biotecnologica in fase clinica, ha annunciato la sua partecipazione al Stifel Virtual Inflammation & Immunology Summit il 17 e 18 settembre. La società presenterà martedì 17 settembre, alle 13:00 PT / 16:00 ET, offrendo una panoramica dei suoi:

  • Programmi e piattaforma di inibitori multi-citochinici
  • Focus su indicazioni dermatologiche e gastrointestinali
  • Sviluppo in corso di itolizumab in collaborazione con Ono Pharmaceutical
  • Decisione pendente di Ono sull'esercizio dell'opzione per potenzialmente acquisire i diritti di Equillium su itolizumab

La direzione sarà disponibile per incontri individuali durante la conferenza. Una registrazione della presentazione sarà accessibile sul sito web dell'azienda, con una riproduzione archiviata disponibile per 90 giorni.

Equillium, Inc. (Nasdaq: EQ), una empresa de biotecnología en etapa clínica, ha anunciado su participación en el Stifel Virtual Inflammation & Immunology Summit los días 17 y 18 de septiembre. La empresa presentará el martes 17 de septiembre, a la 1:00 p.m. PT / 4:00 p.m. ET, proporcionando una visión general de sus:

  • Programas y plataforma de inhibidores de múltiples citoquinas
  • Enfoque en indicaciones dermatológicas y gastrointestinales
  • Desarrollo en curso de itolizumab en asociación con Ono Pharmaceutical
  • Decisión pendiente de Ono sobre el ejercicio de la opción para potencialmente adquirir los derechos de Equillium sobre itolizumab

La dirección estará disponible para reuniones uno a uno durante la conferencia. Una transmisión de la presentación estará disponible en el sitio web de la empresa, con una repetición archivada durante 90 días.

Equillium, Inc. (Nasdaq: EQ), 임상 단계의 생명 공학 회사가 9월 17일과 18일에 열리는 Stifel Virtual Inflammation & Immunology Summit에 참여한다고 발표했습니다. 회사는 9월 17일 화요일 오후 1시 PT / 오후 4시 ET에 발표를 진행하며, 다음과 같은 내용을 포함한 개요를 제공할 예정입니다:

  • 다중 사이토카인 억제제 프로그램 및 플랫폼
  • 피부과 및 위장관 적응증에 중점
  • 오노 제약과의 파트너십에 따른 itolizumab의 지속적인 개발
  • Equillium의 itolizumab에 대한 권리를 잠재적으로 인수하기 위해 오노의 옵션 행사 결정 대기 중

경영진은 회의 동안 개별 회의에 참석할 수 있습니다. 발표의 웹캐스트는 회사 웹사이트에서 접근 가능하며, 90일 동안 아카이브 재생이 가능합니다.

Equillium, Inc. (Nasdaq: EQ), une entreprise de biotechnologie en phase clinique, a annoncé sa participation au Stifel Virtual Inflammation & Immunology Summit les 17 et 18 septembre. L'entreprise fera une présentation le mardi 17 septembre à 13h00 PT / 16h00 ET, fournissant un aperçu de ses:

  • Programmes et plateforme d'inhibiteurs multi-cytokines
  • Concentration sur les indications dermatologiques et gastro-intestinales
  • Développement en cours de l'itolizumab en partenariat avec Ono Pharmaceutical
  • Décision en attente d'Ono sur l'exercice de l'option pour éventuellement acquérir les droits d'Equillium sur l'itolizumab

La direction sera disponible pour des réunions individuelles pendant la conférence. Un webinaire de la présentation sera accessible sur le site web de l'entreprise, avec une rediffusion archivée disponible pendant 90 jours.

Equillium, Inc. (Nasdaq: EQ), ein biotechnologisches Unternehmen in der klinischen Phase, hat seine Teilnahme am Stifel Virtual Inflammation & Immunology Summit am 17. und 18. September bekannt gegeben. Das Unternehmen wird am Dienstag, den 17. September, um 13:00 Uhr PT / 16:00 Uhr ET präsentieren und eine Übersicht über seine:

  • Multi-Zytokin-Inhibitoren-Programme und Plattform
  • Fokus auf dermatologische und gastrointestinale Indikationen
  • Fortlaufende Entwicklung von Itolizumab in Partnerschaft mit Ono Pharmaceutical
  • Ausstehende Option von Ono zur potenziellen Übernahme der Rechte von Equillium an Itolizumab

Das Management wird während der Konferenz für persönliche Treffen zur Verfügung stehen. Ein Webcast der Präsentation wird auf der Website des Unternehmens zugänglich sein, mit einer archivierten Wiedergabe, die 90 Tage verfügbar ist.

Positive
  • None.
Negative
  • None.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present and host investor meetings at the Stifel Virtual Inflammation & Immunology Summit taking place on September 17 & 18.

Management will provide an overview of the Company’s multi-cytokine inhibitor programs and platform, currently focused on dermatological and gastrointestinal indications, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical and Ono’s pending option exercise decision to potentially acquire Equillium’s rights to itolizumab. Management will be available for one-on-one meetings during the conference.

Conference:

Location:          

Dates:                

Presentation: 

Stifel Virtual Inflammation & Immunology Summit

Virtual

Tuesday, September 17 & Wednesday, September 18

Tuesday, September 17, 1:00 pm Pacific Time | 4:00 pm Eastern Time

Webcast access for the Virtual Summit presentation will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of the presentation will be available for 90 days.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development. The multi-cytokine platform: generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and announced positive data from a Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd., for the development and commercialization of itolizumab under an option and asset purchase agreement.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com

Source: Equillium, Inc.

FAQ

When is Equillium (EQ) presenting at the Stifel Virtual Inflammation & Immunology Summit?

Equillium (EQ) is presenting at the Stifel Virtual Inflammation & Immunology Summit on Tuesday, September 17, at 1:00 pm Pacific Time / 4:00 pm Eastern Time.

What will Equillium (EQ) discuss during its presentation at the Stifel Summit?

Equillium (EQ) will provide an overview of its multi-cytokine inhibitor programs and platform, focusing on dermatological and gastrointestinal indications, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical.

How can investors access Equillium's (EQ) presentation at the Stifel Summit?

Investors can access the webcast of Equillium's (EQ) presentation on the Events & Presentations page under the Investor Relations tab on the company's website. An archived replay will be available for 90 days.

What is the significance of Ono Pharmaceutical's pending decision for Equillium (EQ)?

Ono Pharmaceutical has a pending option exercise decision to potentially acquire Equillium's (EQ) rights to itolizumab, which could significantly impact Equillium's development and commercialization plans for the drug.

Equillium, Inc.

NASDAQ:EQ

EQ Rankings

EQ Latest News

EQ Stock Data

25.47M
22.50M
36.21%
20.04%
0.33%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA